Public deck

Amgen: the post-Horizon biotech has to turn scale into deleveraging and pipeline proof

Amgen reported FY2025 revenue of $36.75 billion and Q1 2026 revenue of $8.62 billion, with the official record tying the thesis to biologics scale, acquired-product integration, patent cliffs, pipeline execution, leverage and cash conversion.